Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for Radioiodine Therapy in Benign Non-toxic Nodular Goiter
NCT00275171Phase 2Completed
- Start
- Feb 2006
- Primary completion
- Apr 2009
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-toxic multinodular goiter comparing rhTSH Group with Placebo Group (2 arms). Primary endpoints: Thyroid 131I-uptake at 96 hours, Optimal Time Interval for rhTSH Injection at 96 hours and 1 more. Started Feb 2006; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
Non-toxic multinodular goiter
Beyond the preview
Go deeper on NCT00275171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275171.